David Stamler, M.D.
Chief Executive Officer at Alterity Therapeutics
LinkedIn Profile: [David Stamler - LinkedIn](https://www.linkedin.com/in/david-stamler-b731a11b)
Professional Background
Dr. David Stamler has an extensive career in pharmaceutical development particularly focusing on neurological conditions, evident from his previous roles and achievements.
Current Position:
- Chief Executive Officer at Alterity Therapeutics (January 2021 - Present)
- Succeeded Mr. Geoffrey Kempler, the founder of the company.
- Leads the company's strategic direction and commercial activities.
- Instrumental in advancing the lead compound ATH434 to Phase 2 Clinical Trials.
Past Positions:
- Chief Medical Officer and Senior Vice President, Clinical Development at Alterity Therapeutics (June 2017 - December 2020)
- Vice President, Clinical Development and Therapeutic Head for Movement Disorders at Teva Pharmaceutical Industries (2015 - 2017)
- Chief Medical Officer at Auspex Pharmaceuticals (January 2011 - 2015)
- Senior Vice President and Chief Medical Officer at XenoPort, Inc. (2008 - 2010)
- Chief Scientific Officer and Head of Drug Development at Prestwick Pharmaceuticals, Inc. (2005 - 2008)
- Vice President, Research and Development, Medical Sciences at Fujisawa Healthcare, Inc. (2003 - 2005)
- Director of Clinical Research, Pharmaceutical Products at Abbott Laboratories (1993 - 1997)
Education
- Doctor of Medicine (M.D.) from the University of Chicago, The Pritzker School of Medicine.
- Bachelor of Arts (B.A.) in Biology from the University of Chicago.
Key Achievements and Contributions
- Successfully led the clinical development and approval of three New Drug Applications with the US FDA, focused on neurological diseases.
- At Alterity Therapeutics, Dr. Stamler has been pivotal in the ongoing development and clinical trials of ATH434, a promising treatment for neurodegenerative diseases.
- As CEO, he has emphasized advancing the company’s commercial strategies and preparing its lead compound for later-stage trials.
- Published numerous studies and presented at several high-profile conferences such as the SHARE Series and MST Financial Webinars.
Recent Activities
- Shareholder Engagement: Issued letters and hosted webcasts discussing pipeline progress and new data releases.
- Webcast Presentation on New Data from the bioMUSE Natural History Study (May 29, 2024)
- Presentation on ATH434 Efficacy Data in Primates (December 4, 2023)
- Investor Relations: Frequently participates in investor-centric events to discuss Alterity Therapeutics' progress and future milestones.
- SHARE Series Monday Management Update (May 22, 2023)
- MST Financial ‘Hidden Gems in Life Sciences’ Webinar
Company Overview: Alterity Therapeutics
Alterity Therapeutics (formerly known as Prana Biotechnology) focuses on the development of therapeutic treatments for neurodegenerative diseases such as Parkinson’s disease and Multiple System Atrophy (MSA). The company’s lead compound, ATH434, is progressing through Phase 2 Clinical Trials, showing potential efficacy in treating rare neurodegenerative conditions.
Recent Financial Performance:
- The company raised AUD 3.25 million in a recent placement (February 23, 2024), underscoring the ongoing financial activities to support clinical developments.
Miscellaneous
- Instrumental in fostering partnerships and corporate governance within Alterity Therapeutics.
- Actively engaged in strategic planning and execution of clinical trials to enhance therapeutic outcomes for neurodegenerative disease patients.
This dossier compiles critical professional and organizational insights about Dr. David Stamler, underscoring his leadership role at Alterity Therapeutics and reflecting on his extensive background in clinical development within the pharmaceutical industry.
